DNA-PK inhibitors to reduce HIV gene expression
Official title: DNA-PK inhibition to abolish HIV gene products
Funded at Thomas Jefferson University · NIH-11420070 · Data updated 2026-11-12
A patient-focused project to test whether a DNA-PK inhibitor can safely reduce HIV RNA and proteins in people living with HIV who are on ART.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 9, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $803,550 |
| NIH project number | 1R01AI200840-01 |
| Project ID | NIH-11420070 on NIH RePORTER |
Who could benefit from this research
✓Could help
People living with HIV who are on effective ART and have residual immune activation may be eligible.
✕Less likely to help
Patients with adverse reactions to DNA-PK inhibitors or without residual inflammation may not benefit.
What this research studies
This project aims to see if a carefully dosed DNA-PK inhibitor can lower HIV transcription in people taking ART, with the goal of reducing ongoing inflammation. Researchers will test safety and the potential to suppress HIV transcripts in patient-derived cells and explore how this approach affects immune activation. The study builds on prior lab findings and plans to move carefully from preclinical data toward early human insights, prioritizing tolerability and targeted effects. If successful, this could lead to new strategies that complement ART to improve long-term health for people living with HIV.
Why it matters
Potential benefit: If successful, the approach could lessen persistent inflammation and enhance HIV control beyond current ART.
How similar studies have gone: Prior lab work suggests partial DNA-PK inhibition can reduce HIV transcription with limited impact on normal cell function, making this a promising but early effort.
Where this research is happening
-
Thomas Jefferson University
Philadelphia, United States Active
Researchers
- Principal investigator: Tyagi, Mudit — Thomas Jefferson University
- Study coordinator: Tyagi, Mudit
Related research
Other NIH-funded projects on the same topics.
-
Understanding CAG repeat instability in Huntington’s disease
A Huntington’s disease study explores why the CAG repeat in the HTT gene becomes unstable and leads to earlier disease, aiming to uncover factors that influence when and how the disease starts.
-
Noninvasive portal pressure estimation using ultrasound-based subharmonic signals
A noninvasive ultrasound method to estimate portal vein pressure in adults with cirrhosis to help manage varices and ascites.
-
Twice-reading RNA sequencing to better map RNA modifications
Researchers are using a novel method to read RNA twice to more accurately map chemical modifications in human transcripts, which could help us understand health and disease.
-
Improving HIV Prevention for Women in ObGyn Care
Aimed at helping women in obstetric/gynecologic care reduce their risk of HIV by making PrEP and risk–screening more accessible and acceptable.
-
Immunostimulatory short non-coding RNAs and lupus
A study in people with lupus looks at tiny RNA pieces that may spark inflammation, to understand if they drive disease activity.
-
Global Network for Women’s and Children’s Health: New Cycle Leadership and Collaboration
A long-standing collaboration between TJU and JNMC is expanding to lead and coordinate efforts to improve the health of mothers and young children in low-resource settings.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.